Teva keeps the faith after another rebuke for Copaxone’s heir

Damian Garde Teva's $ 4-billion-a-year multiple sclerosis treatment Copaxone is slated to lose patent protection next year, and the Israeli drugmaker is struggling to move the ...

Isarna snags another $7.6M to advance its cancer immunotherapy

Damian Garde After shifting its focus from antisense therapies to immuno-oncology last year, Germany's Isarna Therapeutics has pulled down $ 7.6 million to jump-start the development ...

Teva stands by its MS pill after yet another setback

Damian Garde European regulators recommended against Teva Pharmaceutical's laquinimod, marring the Isreali company's odds of crossing the finish line with its once-promising ...

Painful Erections: Another Reason To Worry About ADHD Pills

esilverman For parents who worry those ADHD pills may not be appropriate, here is another reason for concern – the FDA has just issued a notice saying methylphenidate products, ...

Eisai bets another $60M on Arena’s Belviq with worldwide marketing deal

Tracy Staton Eisai gave Arena Pharmaceuticals' obesity drug Belviq another vote of confidence. The Japanese drugmaker, already marketing the drug in the U.S., signed up to promote ...

Amarin suffers another blow at the hands of the FDA

John Carroll Already suffering from an expert panel rejection for an expanded label on its cholesterol drug Vascepa, Amarin was subjected to another drubbing on Wall Street after the ...

Alexion bags another FDA ‘breakthrough’ for rare-disease drug

Damian Garde Alexion Pharmaceuticals has racked up its second breakthrough therapy designation from the FDA, securing a faster track for an early-phase enzyme-replacement treatment ...

NEA-backed orphan-drug accelerator bags another $10M

Damian Garde Cydan, an orphan-drug accelerator bankrolled by New Enterprise Associates and Pfizer Ventures, has secured another $ 10 million in venture cash. FierceBiotech News

Roche lung cancer drug bags another ‘breakthrough’ at the FDA

John Carroll Roche has won bragging rights to the FDA's new Breakthrough Therapy designation for its ALK inhibitor alectinib, a non-small cell lung cancer drug which will be featured ...

Merck R&D hammered by another setback as FDA rejects anesthesia drug (again)

John Carroll According to the pharma giant, this latest black eye for the trouble-prone R&D group comes after the FDA "raised concerns about operational aspects of a hypersensitivity ...

Acceleron raises $93M as Celgene, investors rally around another biotech IPO

John Carroll Acceleron will begin trading today under the "XLRN" symbol, part of a burst of new fall IPOs that got started with FivePrime's offering yesterday and is scheduled ...

Another compounder recalls drugs because of lapse in outside testing

Eric Palmer A third compounding pharmacy is recalling sterile injectable drugs nationwide because it can't rely on the results of an outside laboratory that tested them for sterility. ...
Page 4 of 7« First...23456...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS